Detection of a Broad Range of Low-Level Major Histocompatibility Complex Class II-Restricted, Hepatitis Delta Virus (HDV)-Specific T-Cell Responses Regardless of Clinical Status.


Journal

The Journal of infectious diseases
ISSN: 1537-6613
Titre abrégé: J Infect Dis
Pays: United States
ID NLM: 0413675

Informations de publication

Date de publication:
29 01 2019
Historique:
received: 07 05 2018
accepted: 21 09 2018
pubmed: 25 9 2018
medline: 13 11 2019
entrez: 25 9 2018
Statut: ppublish

Résumé

This study aimed to comprehensively define the breadth and specificity of the hepatitis delta virus (HDV)-specific T-cell response in patients at different stages of chronic coinfection with hepatitis B virus (HBV). Following in vitro stimulation with an overlapping set of 21 HDV-specific 20mer peptides and exogenous interleukin 2, HDV-specific CD4+ and CD8+ T-cell responses of 32 HDV-infected patients were analyzed by enzyme-linked immunospot analysis and intracellular cytokine staining for interferon γ production at the single-peptide level. Additionally, HLA-binding studies were performed both in silico and in vitro. We were able to detect ≥1 T-cell response in >50% our patients. Interestingly, there was no significant difference between the breadth of the response in patients positive and those negative for HDV by PCR. HDV-specific T-cell responses focused on 3 distinct HDV-specific epitopes that were each detected in 12%-21% of patients-2 HLA class II-restricted epitopes (amino acids 11-30 and 41-60) and 1 major histocompatibility complex class I-restricted epitope (amino acids 191-210). In in vitro HLA-binding assays, the 2 CD4+ T-cell specificities (amino acids 11-30 and 41-60) showed promiscuous binding to multiple HLA-DR molecules. This comprehensive characterization of HDV T-cell epitopes provides important information that will facilitate further studies of HDV immunopathogenesis.

Sections du résumé

Background
This study aimed to comprehensively define the breadth and specificity of the hepatitis delta virus (HDV)-specific T-cell response in patients at different stages of chronic coinfection with hepatitis B virus (HBV).
Methods
Following in vitro stimulation with an overlapping set of 21 HDV-specific 20mer peptides and exogenous interleukin 2, HDV-specific CD4+ and CD8+ T-cell responses of 32 HDV-infected patients were analyzed by enzyme-linked immunospot analysis and intracellular cytokine staining for interferon γ production at the single-peptide level. Additionally, HLA-binding studies were performed both in silico and in vitro.
Results
We were able to detect ≥1 T-cell response in >50% our patients. Interestingly, there was no significant difference between the breadth of the response in patients positive and those negative for HDV by PCR. HDV-specific T-cell responses focused on 3 distinct HDV-specific epitopes that were each detected in 12%-21% of patients-2 HLA class II-restricted epitopes (amino acids 11-30 and 41-60) and 1 major histocompatibility complex class I-restricted epitope (amino acids 191-210). In in vitro HLA-binding assays, the 2 CD4+ T-cell specificities (amino acids 11-30 and 41-60) showed promiscuous binding to multiple HLA-DR molecules.
Conclusions
This comprehensive characterization of HDV T-cell epitopes provides important information that will facilitate further studies of HDV immunopathogenesis.

Identifiants

pubmed: 30247653
pii: 5106138
doi: 10.1093/infdis/jiy549
doi:

Substances chimiques

Cytokines 0
Epitopes, T-Lymphocyte 0
Histocompatibility Antigens Class II 0

Types de publication

Journal Article Research Support, Non-U.S. Gov't

Langues

eng

Sous-ensembles de citation

IM

Pagination

568-577

Auteurs

Johanna Landahl (J)

I. Department of Medicine, Section Infectious Diseases, Hamburg, Germany.

Jan Hendrik Bockmann (JH)

I. Department of Medicine, Section Infectious Diseases, Hamburg, Germany.
German Center for Infection Research Partner Site, Hamburg, Germany.

Christoph Scheurich (C)

I. Department of Medicine, Section Infectious Diseases, Hamburg, Germany.

Christin Ackermann (C)

I. Department of Medicine, Section Infectious Diseases, Hamburg, Germany.

Verena Matzat (V)

I. Department of Medicine, Section Infectious Diseases, Hamburg, Germany.

Janna Heide (J)

I. Department of Medicine, Section Infectious Diseases, Hamburg, Germany.
German Center for Infection Research Partner Site, Hamburg, Germany.

Tungalag Nuurei (T)

Department of Medical Microbiology, University Medical Center Hamburg-Eppendorf, Hamburg, Germany.

Gianluca D'Antonio (G)

I. Department of Medicine, Section Infectious Diseases, Hamburg, Germany.

Johann von Felden (J)

I. Department of Medicine, Section Infectious Diseases, Hamburg, Germany.

Alessandro Sette (A)

La Jolla Institute for Allergy and Immunology, California.

Sven Peine (S)

Department of Transfusion Medicine, Hamburg, Germany.

Ansgar W Lohse (AW)

I. Department of Medicine, Section Infectious Diseases, Hamburg, Germany.
German Center for Infection Research Partner Site, Hamburg, Germany.

Marc Luetgehetmann (M)

Department of Medical Microbiology, University Medical Center Hamburg-Eppendorf, Hamburg, Germany.
German Center for Infection Research Partner Site, Hamburg, Germany.

Matthias Marget (M)

Department of Transfusion Medicine, Hamburg, Germany.

John Sidney (J)

La Jolla Institute for Allergy and Immunology, California.

Julian Schulze Zur Wiesch (J)

I. Department of Medicine, Section Infectious Diseases, Hamburg, Germany.
German Center for Infection Research Partner Site, Hamburg, Germany.

Articles similaires

[Redispensing of expensive oral anticancer medicines: a practical application].

Lisanne N van Merendonk, Kübra Akgöl, Bastiaan Nuijen
1.00
Humans Antineoplastic Agents Administration, Oral Drug Costs Counterfeit Drugs

Smoking Cessation and Incident Cardiovascular Disease.

Jun Hwan Cho, Seung Yong Shin, Hoseob Kim et al.
1.00
Humans Male Smoking Cessation Cardiovascular Diseases Female
Humans United States Aged Cross-Sectional Studies Medicare Part C
1.00
Humans Yoga Low Back Pain Female Male

Classifications MeSH